Hyperbaric Oxygen Treatment for Long COVID: From Molecular Mechanism to Clinical Practice

Abstract

Long COVID symptoms typically occur within 3 months of an initial COVID-19 infection, last for more than 2 months, and cannot be explained by other diagnoses. The most common symptoms include fatigue, dyspnea, coughing, and cognitive impairment. The mechanisms of long COVID are not fully understood, but several hypotheses have been put forth. These include coagulation and fibrosis pathway activation, inflammatory and autoimmune manifestations, persistent virus presence, and Epstein-Barr virus reactivation. Hyperbaric oxygen therapy (HBOT) is a therapeutic method in which a person inhales 100% oxygen under pressure greater than that of the atmosphere. HBOT has some therapeutic effects, including improvement of microcirculation, inhibition of cytokine release leading to a reduction in inflammatory responses, inhibition of autoimmune responses, and promotion of neurological repair. Several clinical trials have been carried out using HBOT to treat long COVID. The results suggest that HBOT helps to improve symptom severity, reduce symptom duration, and enhance patients’ quality of life. It is believed that HBOT is an effective option for patients with long COVID, which is worth actively promoting.

Keywords

long COVID / post-COVID-19 condition / SARS-CoV-2 / hyperbaric oxygen therapy

References

[1] BalleringAV, van ZonSKR, Olde HartmanTC, et al.. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet, 2022, 400(10350): 452-461

[2] AyoubkhaniD, BerminghamC, PouwelsKB, et al.. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ, 2022, 377: e069676

[3] ShahW, HillmanT, PlayfordED, et al.. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ, 2021, 372: n136

[4] O’MahoneyLL, RoutenA, GilliesC, et al.. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine, 2023, 55: 101762

[5] Wulf HansonS, AbbafatiC, AertsJG, et al.. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA, 2022, 328(16): 1604-1615

[6] HuangL, LiX, GuX, et al.. Health outcomes in people years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med, 2022, 10(9): 863-876

[7] BoweB, XieY, Al-AlyZ. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med, 2022, 28(11): 2398-2405

[8] SubramanianA, NirantharakumarK, HughesS, et al.. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med, 2022, 28(8): 1706-1714

[9] KatsoularisI, Fonseca-RodriguezO, FarringtonP, et al.. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ, 2022, 377: e069590

[10] FogartyH, TownsendL, MorrinH, et al.. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost, 2021, 19(10): 2546-2553

[11] FogartyH, WardSE, TownsendL, et al.. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost, 2022, 20(10): 2429-2438

[12] PretoriusE, VenterC, LaubscherGJ, et al.. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol, 2022, 21(1): 148

[13] PhetsouphanhC, DarleyDR, WilsonDB, et al.. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol, 2022, 23(2): 210-216

[14] PascoliniS, VanniniA, DeleonardiG, et al.. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?. Clin Transl Sci, 2021, 14(2): 502-508

[15] WangEY, MaoT, KleinJ, et al.. Diverse functional autoantibodies in patients with COVID-19. Nature, 2021, 595(7866): 283-288

[16] KovarikJJ, BileckA, HagnG, et al.. A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome. iScience, 2023, 26(1): 105717

[17] RheaEM, LogsdonAF, HansenKM, et al.. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci, 2021, 24(3): 368-378

[18] FrereJJ, SerafiniRA, PryceKD, et al.. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med, 2022, 14(664): eabq3059

[19] SoungAL, VanderheidenA, NordvigAS, et al.. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain, 2022, 145(12): 4193-4201

[20] SolomonT. Neurological infection with SARS-CoV-2 - the story so far. Nat Rev Neurol, 2021, 17(2): 65-66

[21] MatschkeJ, LutgehetmannM, HagelC, et al.. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol, 2020, 19(11): 919-929

[22] SteinSR, RamelliSC, GrazioliA, et al.. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022, 612(7941): 758-763

[23] SunJ, XiaoJ, SunR, et al.. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg Infect Dis, 2020, 26(8): 1834-1838

[24] VibholmLK, NielsenSSF, PahusMH, et al.. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine, 2021, 64: 103230

[25] PelusoMJ, DeveauTM, MunterSE, et al.. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest, 2023, 133(3): e163669

[26] GodmanCA, ChhedaKP, HightowerLE, et al.. Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones, 2010, 15(4): 431-442

[27] GregorevicP, LynchGS, WilliamsDA. Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol, 2001, 86(1): 24-27

[28] BensonRM, MinterLM, OsborneBA, et al.. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocytemacrophages. Clin Exp Immunol, 2003, 134(1): 57-62

[29] MoonBI, KimHR, ChoiEJ, et al.. Attenuation of collagen-induced arthritis by hyperbaric oxygen therapy through altering immune balance in favor of regulatory T cells. Undersea Hyperb Med, 2017, 44(4): 321-330

[30] YangYJ, WangXL, YuXH, et al.. Hyperbaric oxygen induces endogenous neural stem cells to proliferate and differentiate in hypoxic-ischemic brain damage in neonatal rats. Undersea Hyperb Med, 2008, 35(2): 113-129

[31] GutsaevaDR, SulimanHB, CarrawayMS, et al.. Oxygen-induced mitochondrial biogenesis in the rat hippocampus. Neuroscience, 2006, 137(2): 493-504

[32] DavisCH, KimKY, BushongEA, et al.. Transcellular degradation of axonal mitochondria. Proc Natl Acad Sci USA, 2014, 111(26): 9633-9638

[33] PaganiniM, BoscoG, PerozzoFAG, et al.. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review. Adv Exp Med Biol, 2021, 1289: 27-35

[34] SenS, SenS. Therapeutic effects of hyperbaric oxygen: integrated review. Med Gas Res, 2021, 11(1): 30-33

[35] HarchPG. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res, 2020, 10(2): 61-62

[36] RobbinsT, GonevskiM, ClarkC, et al.. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond), 2021, 21(6): e629-e632

[37] CatalognaM, SassonE, HadannyA, et al.. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trial. Neuroimage Clin, 2022, 36: 103218

[38] Zilberman-ItskovichS, CatalognaM, SassonE, et al.. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep, 2022, 12(1): 11252

[39] ZantAE, FigueroaXA, PaulsonCP, et al.. Hyperbaric oxygen therapy to treat lingering COVID-19 symptoms. Undersea Hyperb Med, 2022, 49(3): 333-339

[40] KjellbergA, Abdel-HalimL, HasslerA, et al.. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open, 2022, 12(11): e061870

[41] NunnAVW, GuyGW, BryschW, et al.. Understanding Long COVID; Mitochondrial Health and Adaptation-Old Pathways, New Problems. Biomedicines, 2022, 10(12): 3113

[42] SchottlenderN, GottfriedI, AsheryU. Hyperbaric Oxygen Treatment: Effects on Mitochondrial Function and Oxidative Stress. Biomolecules, 2021, 11(12): 1827

[43] LiuZ, KilicG, LiW, et al.. Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Front Immunol, 2022, 13: 838132

[44] BalnisJ, MadridA, HoganKJ, et al.. Persistent blood DNA methylation changes one year after SARS-CoV-2 infection. Clin Epigenetics, 2022, 14(1): 94

[45] CaoX, LiW, WangT, et al.. Accelerated biological aging in COVID-19 patients. Nat Commun, 2022, 13(1): 2135

[46] MongelliA, BarbiV, Gottardi ZamperlaM, et al.. Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors. Int J Mol Sci, 2021, 22(11): 6151

[47] HachmoY, HadannyA, Abu HamedR, et al.. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY), 2020, 12(22): 22445-22456

[48] LiuK, WuH, GaoR, et al.. DNA Methylation May be Involved in the Analgesic Effect of Hyperbaric Oxygen via Regulating FUNDC1. Pain Res Manag, 2020, 2020: 1528362

[49] KjellbergA, HasslerA, BoströmE, et al.. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis, 2023, 23(1): 33

[50] LeitmanM, FuchsS, TyomkinV, et al.. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial. Sci Rep, 2023, 13(1): 9473